Respiratorius AB (publ)
Respiratorius AB (publ), a research company, develops pharmaceuticals for the treatment of cancer. The company's products under development include VAL001, that is in Phase III clinical trials for the treatment of diffuse large B-cell lymphoma; and VAL001, a product candidate that is in preclinical phase for the treatment of relapsing diffuse large B-cell lymphoma. Respiratorius AB (publ) was inc… Read more
Respiratorius AB (publ) (HF00) - Net Assets
Latest net assets as of September 2025: €32.29 Million EUR
Based on the latest financial reports, Respiratorius AB (publ) (HF00) has net assets worth €32.29 Million EUR as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€33.20 Million) and total liabilities (€913.00K). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €32.29 Million |
| % of Total Assets | 97.25% |
| Annual Growth Rate | -19.08% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 22.18 |
Respiratorius AB (publ) - Net Assets Trend (2021–2024)
This chart illustrates how Respiratorius AB (publ)'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Respiratorius AB (publ) (2021–2024)
The table below shows the annual net assets of Respiratorius AB (publ) from 2021 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €30.10 Million | +13.56% |
| 2023-12-31 | €26.50 Million | -22.80% |
| 2022-12-31 | €34.33 Million | -39.57% |
| 2021-12-31 | €56.81 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Respiratorius AB (publ)'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 756600000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €37.66 Million | 125.14% |
| Total Equity | €30.10 Million | 100.00% |
Respiratorius AB (publ) Competitors by Market Cap
The table below lists competitors of Respiratorius AB (publ) ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
PRINCIPAL FINANCIAL (PG4.SG)
STU:PG4
|
$752.69K |
|
Top Systems-L
TA:TOPS
|
$753.78K |
|
GRACO (GA8.SG)
STU:GA8
|
$754.30K |
|
IMPLENIA N (I8T.SG)
STU:I8T
|
$754.32K |
|
SHAREHOLD VAL BET. - Dusseldorf Stock Exchang
DU:SVE
|
$751.18K |
|
Heartbeam Inc. Warrant
NASDAQ:BEATW
|
$750.91K |
|
NETFONDS AG VNA O.N.
F:NF4
|
$750.65K |
|
GAS2GRID Ltd
AU:GGX
|
$750.13K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Respiratorius AB (publ)'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 26,502,292 to 30,095,395, a change of 3,593,103 (13.6%).
- Net loss of 7,565,731 reduced equity.
- New share issuances of 11,158,834 increased equity.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-7.57 Million | -25.14% |
| Share Issuances | €11.16 Million | +37.08% |
| Total Change | €- | 13.56% |
Book Value vs Market Value Analysis
This analysis compares Respiratorius AB (publ)'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.02x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | €24.48 | €0.10 | x |
| 2022-12-31 | €11.74 | €0.10 | x |
| 2023-12-31 | €9.07 | €0.10 | x |
| 2024-12-31 | €5.90 | €0.10 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Respiratorius AB (publ) utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -25.14%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.03x
- Recent ROE (-25.14%) is below the historical average (-23.88%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | -16.97% | 0.00% | 0.00x | 1.09x | €-15.32 Million |
| 2023 | -29.54% | 0.00% | 0.00x | 1.05x | €-10.48 Million |
| 2024 | -25.14% | 0.00% | 0.00x | 1.03x | €-10.58 Million |
Industry Comparison
This section compares Respiratorius AB (publ)'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,291,084,078
- Average return on equity (ROE) among peers: -24.49%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Respiratorius AB (publ) (HF00) | €32.29 Million | -16.97% | 0.03x | $752.26K |
| 09R (09R) | $-3.01 Million | 0.00% | 0.00x | $11.12 Million |
| IDORSIA AG (19T) | $-968.72 Million | 0.00% | 0.00x | $532.51 Million |
| 1S90 (1S90) | $-44.86 Million | 0.00% | 0.00x | $51.72 Million |
| Strategic Partners A/S (1TB0) | $14.24 Million | -182.90% | 0.36x | $1.31 Million |
| 25K0 (25K0) | $-16.66 Million | 0.00% | 0.00x | $102.39 Million |
| 2BO (2BO) | $-37.78 Million | 0.00% | 0.00x | $6.23 Million |
| Intervacc AB (publ) (2E9) | $237.93 Million | -43.23% | 0.09x | $3.46 Million |
| 2F5 (2F5) | $-4.57 Million | 0.00% | 0.00x | $2.14 Million |
| 2H0 (2H0) | $14.92 Million | -17.30% | 0.56x | $9.25 Million |
| GNI Group Ltd (3G6) | $13.72 Billion | -1.46% | 0.26x | $772.60 Million |